Electroporation uses short electric pulses to create transient pores in a cell’s membrane, allowing researchers to deliver intracellular molecules for cell engineering, gene expression studies, ...

Current data on the use of irreversible electroporation (IRE) in the treatment of prostate cancer (PCa) is limited. We aim to evaluate the safety, short-term functional and oncological outcomes of ...

Treatment uses electric pulses to kill prostate cancer cells while minimising risks of incontinence and sexual dysfunction.

Electroporation works well with cell lines that are refractive to other techniques, such as calcium phosphate–DNA coprecipitation. But as with other transfection methods, the optimal conditions ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR-T cell therapy program for autoimmune diseases.

You don't want to miss this! To permanently access these supporting documents, fill out the short form below. At MaxCyte, we share your passion for the discovery, development, and manufacturing of ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based ...

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...

ei=1703585&tp_key=2c4874e6e2 Event Overview Attendees will gain insights into the NanoKnife System’s proprietary irreversible electroporation (IRE) technology and how it is poised to become the ...

To permanently access these supporting documents, fill out the short form below. At MaxCyte, we share your passion for the discovery, development, and manufacturing of next generation therapies, ...